Enveric Biosciences, Inc.
ENVB
$1.30
$0.043.18%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.36M | 2.23M | 1.24M | 1.30M | 1.89M |
| Depreciation & Amortization | 81.00K | 82.50K | 84.80K | 84.80K | 85.40K |
| Other Operating Expenses | -- | -246.10K | -- | -- | -- |
| Total Operating Expenses | 2.19M | 3.17M | 2.08M | 1.90M | 2.48M |
| Operating Income | -2.19M | -3.17M | -2.08M | -1.90M | -2.48M |
| Income Before Tax | -2.19M | -3.15M | -2.08M | -1.88M | -2.46M |
| Income Tax Expenses | -- | 7.20K | -- | -- | 1.70K |
| Earnings from Continuing Operations | -2.19M | -3.15M | -2.08M | -1.88M | -2.46M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.19M | -3.15M | -2.08M | -1.88M | -2.46M |
| EBIT | -2.19M | -3.17M | -2.08M | -1.90M | -2.48M |
| EBITDA | -2.11M | -3.09M | -2.00M | -1.81M | -2.39M |
| EPS Basic | -1.22 | -4.80 | -3.59 | -3.72 | -9.21 |
| Normalized Basic EPS | -0.76 | -2.99 | -2.25 | -2.32 | -5.75 |
| EPS Diluted | -1.22 | -4.80 | -3.59 | -3.72 | -9.21 |
| Normalized Diluted EPS | -0.76 | -2.99 | -2.25 | -2.32 | -5.75 |
| Average Basic Shares Outstanding | 1.80M | 657.40K | 580.20K | 505.90K | 266.80K |
| Average Diluted Shares Outstanding | 1.80M | 657.40K | 580.20K | 505.90K | 266.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |